Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBITDA Margin: 2022-2025

Historic EBITDA Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -162.54%.

  • InMed Pharmaceuticals' EBITDA Margin fell 2643.00% to -162.54% in Q3 2025 from the same period last year, while for Sep 2025 it was -166.64%, marking a year-over-year decrease of 2127.00%. This contributed to the annual value of -159.76% for FY2025, which is 1747.00% up from last year.
  • InMed Pharmaceuticals' EBITDA Margin amounted to -162.54% in Q3 2025, which was down 17.31% from -138.56% recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year EBITDA Margin high stood at -20.43% for Q2 2023, and its period low was -1,528.88% during Q2 2022.
  • Its 3-year average for EBITDA Margin is -160.14%, with a median of -158.12% in 2024.
  • In the last 5 years, InMed Pharmaceuticals' EBITDA Margin skyrocketed by 150,844bps in 2023 and then crashed by 13,769bps in 2024.
  • Over the past 4 years, InMed Pharmaceuticals' EBITDA Margin (Quarterly) stood at -447.25% in 2022, then skyrocketed by 31,576bps to -131.49% in 2023, then plummeted by 7,017bps to -201.65% in 2024, then slumped by 2,643bps to -162.54% in 2025.
  • Its EBITDA Margin stands at -162.54% for Q3 2025, versus -138.56% for Q2 2025 and -168.46% for Q1 2025.